Name | Type | Posted | Actions |
|---|---|---|---|
RFP 75A50121R00013 Pages 1-2 9-10-2021.pdf | Sep 10, 2021 | ||
Amendment 4 - Summary.pdf | Sep 10, 2021 | ||
RFP SOW-New Stockpile Updated with Responses 9-2-2021.pdf | Sep 3, 2021 | ||
New Email Account 8-29-2021.pdf | Aug 29, 2021 | ||
Amendment 3 - Past Performance Update v1.pdf | Aug 26, 2021 | ||
Amendment 3 - Past Performance Update.pdf | Aug 25, 2021 | ||
Response - Proposal Ext.pdf | Aug 18, 2021 | ||
QA for Follow-On Stockpile - Additional Questions - 8-16-21 FINAL .pdf | Aug 17, 2021 | ||
QA for Follow Stockpile - IDIQ 8-6-21 FINAL.pdf | Aug 7, 2021 | ||
Amendment 2 - Summary.docx | DOCX | Jul 26, 2021 | |
RFP SOW-New Stockpile 6-29-2021 - Amendment 1.pdf | Jul 23, 2021 | ||
Amendment 1 - Summary.pdf | Jul 23, 2021 | ||
RFP SOW-New Stockpile 6-29-2021 - Program Updated - CLEAN.pdf | Jun 29, 2021 |
Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response
Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response
Contact and place of performance
Wendell Conyers
DC
USA
Reference Amendment 1 PERIOD OF PERFORMANCE a. The base period of performance of this contract is anticipated for thirty-six (36) monthsfrom date of award. The period of performance may be extended up to 24 months withthe exercise of option(s), structured as CLINs. b. If the Government exercises its option(s), the period of performance will be increased as listed below: Option I Twelve (12) Months (Year 4) Option II...
View moreThe Office of the Assistant Secretary for Preparedness and Response (ASPR), through the BARDA Division of Contracts Management and Acquisition, is seeking the acquisition of Medical Countermeasures (MCMs) for pandemic influenza and emerging diseases preparedness and response. This combined synopsis/solicitation, identified by solicitation number 75A50121R00013, requires the production of biological products including cGMP influenza vaccine master and working seed lots, research and investigational lots, and commercial scale bulk lots. The scope encompasses vaccine components such as antigens and adjuvants, as well as formulation, filling, storage, stability testing, and the manufacture of potency reagents and standards. Performance will take place in Washington, DC, under NAICS 325414 for Biological Product (except Diagnostic) Manufacturing and PSC 6505 for Drugs and Biologicals.
The anticipated period of performance consists of a 36-month base period beginning from the date of award, with two optional 12-month extensions that could bring the total duration to five years. Contract deliverables include single-dose and multi-dose vials, syringes, and sprayers for various vaccine and adjuvant formulations, along with comprehensive data reporting and potential non-clinical and clinical studies. The contract established a minimum guarantee of $50,000.00 for the total duration, including all options. Vendors must provide firm-fixed pricing for most line items, while specific tasks related to shipping, analytical testing, and emerging pathogen response will be determined through future Requests for Task Order Response (RTOR).
The response deadline for this solicitation was September 13, 2021. The acquisition process included four amendments, providing updates to the statement of work, past performance requirements, and administrative details. Documentation associated with the notice includes 13 attachments such as the updated Statement of Work for the stockpile, past performance updates, and summary of amendments. The primary point of contact for this requirement is Wendell Conyers.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.